OR WAIT null SECS
January 25, 2017
Researchers from Cellectis investigate how external signals in the tumor microenvironment could control the cell-surface expression and specificity of engineered CARs.
January 24, 2017
Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.
January 19, 2017
Researchers were not able to replicate all of the findings in five highly-cited cancer biology papers.
January 18, 2017
In a blog post, Robert Califf and Rita Nalubola discuss the agency’s approach to the use of genome-edited products.
January 17, 2017
FDA released a long-awaited draft guidance to help sponsors seeking to demonstrate interchangeability for biosimilar products.
January 10, 2017
The membrane-based Protein A purification tool was unveiled at the 2017 PepTalk Conference in San Diego, California.
Language surrounding regenerative medicine and the REGROW Act appeared back into the 21st Century Cures Act right before it passed. What will this mean for the controversial testing and marketing of stem-cell therapies?
January 09, 2017
The companies will combine expertise on T-cell therapies with two or more binding domains to create novel oncology medications.
January 02, 2017
FDA plans to advance initiatives for ensuring reliable production of drugs and biologics in 2017.
December 19, 2016
A pilot project, beginning in 2017, will support the development of biosimilars.